Interim Management Statement on the First Three Months of 2024

  • First efficacy data from the clinical trial with HDP-101 in multiple myeloma
  • Professor Andreas Pahl becomes Chief Executive Officer
  • Successful financing activities
  • Sale of a portion of future royalties for Zircaix™ to HealthCare Royalty finances further development of the ADC pipeline

Ladenburg, Germany, 25 April 2024 – Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2024 (1 December 2023 – 29 February 2024) and the Group’s financial figures.

Read more…